35/120
1.5 / 5 stars
All 120 Win/Lose results shown below
KRYS Roast Me summary
Krystal Biotech, Inc. (KRYS). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
Trailing 1 year (4 quarters): 12 wins, 0 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinKRYS / S&P 43.88% / 15.20% |
WinKRYS / S&P 22.63% / 15.00% |
WinKRYS / S&P 61.87% / 50.40% |
| 2026-Q13/3 |
WinKRYS / S&P 4.78% / -4.33% |
WinKRYS / S&P 25.15% / 11.30% |
WinKRYS / S&P 79.38% / 27.70% |
| 2025-Q43/3 |
WinKRYS / S&P 39.66% / 2.65% |
WinKRYS / S&P 33.94% / 9.00% |
WinKRYS / S&P 128.00% / 13.40% |
| 2025-Q33/3 |
WinKRYS / S&P 28.42% / 8.12% |
WinKRYS / S&P 54.51% / 4.61% |
WinKRYS / S&P 275.28% / 13.45% |
| 2025-Q22/3 |
LoseKRYS / S&P -23.76% / 10.94% |
WinKRYS / S&P 116.09% / 4.83% |
WinKRYS / S&P 34.70% / 10.63% |
| 2025-Q13/3 |
WinKRYS / S&P 15.09% / -4.27% |
WinKRYS / S&P 247.53% / 4.98% |
WinKRYS / S&P 121.81% / 10.57% |
| 2024-Q42/3 |
LoseKRYS / S&P -13.94% / 2.41% |
WinKRYS / S&P 473.02% / 5.25% |
WinKRYS / S&P 669.23% / 6.15% |
| 2024-Q31/3 |
LoseKRYS / S&P -0.88% / 5.89% |
WinKRYS / S&P 2722.79% / 5.89% |
LoseKRYS / S&P KRYS unavailable / 6.11% |
| 2024-Q20/3 |
LoseKRYS / S&P 3.21% / 4.28% |
LoseKRYS / S&P KRYS unavailable / 5.38% |
LoseKRYS / S&P KRYS unavailable / 5.12% |
| 2024-Q11/3 |
WinKRYS / S&P 43.42% / 10.56% |
LoseKRYS / S&P KRYS unavailable / 5.71% |
LoseKRYS / S&P KRYS unavailable / 5.59% |
| 2023-Q40/3 |
LoseKRYS / S&P 6.95% / 11.69% |
LoseKRYS / S&P KRYS unavailable / 6.81% |
LoseKRYS / S&P KRYS unavailable / 7.78% |
| 2023-Q31/3 |
WinKRYS / S&P -1.19% / -3.27% |
LoseKRYS / S&P KRYS unavailable / 7.52% |
LoseKRYS / S&P KRYS unavailable / -5.03% |
| 2023-Q21/3 |
WinKRYS / S&P 46.64% / 8.74% |
LoseKRYS / S&P KRYS unavailable / 9.50% |
LoseKRYS / S&P KRYS unavailable / -8.57% |
| 2023-Q10/3 |
LoseKRYS / S&P 1.06% / 7.50% |
LoseKRYS / S&P KRYS unavailable / 10.77% |
LoseKRYS / S&P KRYS unavailable / -15.69% |
| 2022-Q41/3 |
WinKRYS / S&P 13.66% / 7.56% |
LoseKRYS / S&P KRYS unavailable / 11.88% |
LoseKRYS / S&P KRYS unavailable / -17.99% |
| 2022-Q31/3 |
WinKRYS / S&P 6.15% / -4.88% |
LoseKRYS / S&P KRYS unavailable / 13.47% |
LoseKRYS / S&P KRYS unavailable / -1.41% |
| 2022-Q21/3 |
WinKRYS / S&P -1.32% / -16.10% |
LoseKRYS / S&P KRYS unavailable / 13.71% |
LoseKRYS / S&P KRYS unavailable / 11.04% |
| 2022-Q10/3 |
LoseKRYS / S&P -4.87% / -4.60% |
LoseKRYS / S&P KRYS unavailable / 15.97% |
LoseKRYS / S&P KRYS unavailable / 42.23% |
| 2021-Q41/3 |
WinKRYS / S&P 33.98% / 11.03% |
LoseKRYS / S&P KRYS unavailable / 15.00% |
LoseKRYS / S&P KRYS unavailable / 96.40% |
| 2021-Q30/3 |
LoseKRYS / S&P -23.22% / 0.58% |
LoseKRYS / S&P KRYS unavailable / 10.77% |
LoseKRYS / S&P KRYS unavailable / 69.42% |
| 2021-Q20/3 |
LoseKRYS / S&P -11.73% / 8.55% |
LoseKRYS / S&P KRYS unavailable / 6.58% |
LoseKRYS / S&P KRYS unavailable / 51.81% |
| 2021-Q11/3 |
WinKRYS / S&P 28.40% / 6.17% |
LoseKRYS / S&P KRYS unavailable / -1.06% |
LoseKRYS / S&P KRYS unavailable / 7.39% |
| 2020-Q41/3 |
WinKRYS / S&P 39.37% / 12.15% |
LoseKRYS / S&P KRYS unavailable / -3.72% |
LoseKRYS / S&P KRYS unavailable / -33.42% |
| 2020-Q30/3 |
LoseKRYS / S&P 3.94% / 8.93% |
LoseKRYS / S&P KRYS unavailable / -2.04% |
LoseKRYS / S&P KRYS unavailable / -27.10% |
| 2020-Q20/3 |
LoseKRYS / S&P -4.21% / 20.54% |
LoseKRYS / S&P KRYS unavailable / -0.46% |
LoseKRYS / S&P KRYS unavailable / -27.11% |
| 2020-Q10/3 |
LoseKRYS / S&P -21.92% / -19.60% |
LoseKRYS / S&P KRYS unavailable / 3.47% |
LoseKRYS / S&P KRYS unavailable / -14.75% |
| 2019-Q41/3 |
WinKRYS / S&P 59.48% / 9.07% |
LoseKRYS / S&P KRYS unavailable / 5.36% |
LoseKRYS / S&P KRYS unavailable / 2.99% |
| 2019-Q30/3 |
LoseKRYS / S&P -13.77% / 1.70% |
LoseKRYS / S&P KRYS unavailable / 5.02% |
LoseKRYS / S&P KRYS unavailable / 0.21% |
| 2019-Q21/3 |
WinKRYS / S&P 22.40% / 4.30% |
LoseKRYS / S&P KRYS unavailable / 6.64% |
LoseKRYS / S&P KRYS unavailable / 8.65% |
| 2019-Q11/3 |
WinKRYS / S&P 58.33% / 13.65% |
LoseKRYS / S&P KRYS unavailable / 8.12% |
LoseKRYS / S&P KRYS unavailable / 14.29% |
| 2018-Q41/3 |
WinKRYS / S&P 18.20% / -13.52% |
LoseKRYS / S&P KRYS unavailable / 9.05% |
LoseKRYS / S&P KRYS unavailable / 18.23% |
| 2018-Q31/3 |
WinKRYS / S&P 18.22% / 7.71% |
LoseKRYS / S&P KRYS unavailable / 10.21% |
LoseKRYS / S&P KRYS unavailable / 19.06% |
| 2018-Q21/3 |
WinKRYS / S&P 47.37% / 3.43% |
LoseKRYS / S&P KRYS unavailable / 9.03% |
LoseKRYS / S&P KRYS unavailable / 14.46% |
| 2018-Q10/3 |
LoseKRYS / S&P -4.09% / -0.76% |
LoseKRYS / S&P KRYS unavailable / 7.68% |
LoseKRYS / S&P KRYS unavailable / 12.46% |
| 2017-Q40/3 |
LoseKRYS / S&P 5.52% / 6.64% |
LoseKRYS / S&P KRYS unavailable / 7.03% |
LoseKRYS / S&P KRYS unavailable / 13.82% |
| 2017-Q30/3 |
LoseKRYS / S&P KRYS unavailable / 4.48% |
LoseKRYS / S&P KRYS unavailable / 5.68% |
LoseKRYS / S&P KRYS unavailable / 17.57% |
| 2017-Q20/3 |
LoseKRYS / S&P KRYS unavailable / 3.09% |
LoseKRYS / S&P KRYS unavailable / 4.83% |
LoseKRYS / S&P KRYS unavailable / 17.74% |
| 2017-Q10/3 |
LoseKRYS / S&P KRYS unavailable / 6.07% |
LoseKRYS / S&P KRYS unavailable / 3.67% |
LoseKRYS / S&P KRYS unavailable / 13.32% |
| 2016-Q40/3 |
LoseKRYS / S&P KRYS unavailable / 3.82% |
LoseKRYS / S&P KRYS unavailable / 2.09% |
LoseKRYS / S&P KRYS unavailable / 7.05% |
| 2016-Q30/3 |
LoseKRYS / S&P KRYS unavailable / 3.85% |
LoseKRYS / S&P KRYS unavailable / 0.20% |
LoseKRYS / S&P KRYS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | KRYS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 138.02% | 20.78% |
| Annualized return | 138.02% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | KRYS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 472.01% | 83.14% |
| Annualized return | 41.74% | 12.86% |
10Y · 2017-09-20 to 2026-08-28
| Metric | KRYS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 3204.11% | 319.30% |
| Annualized return | 41.87% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |